Adherence and disease activity outcomes at 12 months
| Intervention | Control | Crude effect estimate (p, 95% CI) | Corrected effect estimate (p, 95% CI) | |
| Primary outcome | ||||
| MPR (SD) | 0.95 (0.10) | 0.90 (0.16) | B: 0.051 (0.009, 0.088 to −0.013) | B: 0.036 (0.045, 0.001 to 0.071)* |
| Proportion adherent, MPR≥0.8 | 92 | 85 | OR 1.63 (0.121, 1.22 to 3.35) | OR 1.83 (0.319, 1.14 to 5.10)* |
| Secondary outcomes | ||||
| Proportion adherent, CQR Zk score | 67 | 75 | OR: 2.01 (0.373, 1.37 to 4.67) | NA |
| Proportion LDA | 75 | 80 | OR: 2.05 (0.352, 1.43 to 4.22) | NA |
| Proportion remission | 56 | 68 | OR: 1.83 (0.101, 1.39 to 3.01) | NA |
*Means and (SD) or proportions are displayed. We corrected for baseline DAS28.
CQR, Compliance Questionnaire in Rheumatology; LDA, Low disease activity; MPR, medication possession ratio.